Genmab | GEN - Equity Capital And Reserves


Genmab reported DKK5.85B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Almirall EUR 1.53B 43.26M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
argenx SE USD 8.42B 1.09B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Bayer EUR 28.85B 2.9B Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Demant DKK 9.84B 446M Dec/2025
Exelixis USD 1.94B 225.57M Mar/2026
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Genmab DKK 5.85B 96M Dec/2025
GlaxoSmithKline GBP 17.64B 223M Jun/2026
GN Store Nord DKK 10.12B 4.76B Mar/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Insmed USD 704.85M 34.12M Mar/2026
Lakefront Biotherapeutics EUR 3.25B 17.5M Mar/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 29.74B 1.15B Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
UCB EUR 10.87B 1.18B Dec/2025